» Articles » PMID: 12093889

Opposite Effects of Cyclooxygenase-1 and -2 Activity on the Pressor Response to Angiotensin II

Overview
Journal J Clin Invest
Specialty General Medicine
Date 2002 Jul 3
PMID 12093889
Citations 80
Authors
Affiliations
Soon will be listed here.
Abstract

Therapeutic use of cyclooxygenase-inhibiting (COX-inhibiting) nonsteroidal antiinflammatory drugs (NSAIDs) is often complicated by renal side effects including hypertension and edema. The present studies were undertaken to elucidate the roles of COX1 and COX2 in regulating blood pressure and renal function. COX2 inhibitors or gene knockout dramatically augment the pressor effect of angiotensin II (Ang II). Unexpectedly, after a brief increase, the pressor effect of Ang II was abolished by COX1 deficiency (either inhibitor or knockout). Ang II infusion also reduced medullary blood flow in COX2-deficient but not in control or COX1-deficient animals, suggesting synthesis of COX2-dependent vasodilators in the renal medulla. Consistent with this, Ang II failed to stimulate renal medullary prostaglandin E(2) and prostaglandin I(2) production in COX2-deficient animals. Ang II infusion normally promotes natriuresis and diuresis, but COX2 deficiency blocked this effect. Thus, COX1 and COX2 exert opposite effects on systemic blood pressure and renal function. COX2 inhibitors reduce renal medullary blood flow, decrease urine flow, and enhance the pressor effect of Ang II. In contrast, the pressor effect of Ang II is blunted by COX1 inhibition. These results suggest that, rather than having similar cardiovascular effects, the activities of COX1 and COX2 are functionally antagonistic.

Citing Articles

Evaluating the Role of Aspirin in Liver Disease: Efficacy, Safety, Potential Benefits and Risks.

Elshaer A, Lizaola-Mayo B Life (Basel). 2025; 14(12.

PMID: 39768407 PMC: 11679757. DOI: 10.3390/life14121701.


Degree of Cyclooxygenase-2 Inhibition Modulates Blood Pressure Response to Celecoxib and Naproxen.

Theken K, Ghosh S, Skarke C, Fries S, Lahens N, Sarantopoulou D medRxiv. 2024; .

PMID: 38854091 PMC: 11160842. DOI: 10.1101/2024.05.30.24308244.


Prostanoids in Cardiac and Vascular Remodeling.

Ricciotti E, Haines P, Chai W, FitzGerald G Arterioscler Thromb Vasc Biol. 2024; 44(3):558-583.

PMID: 38269585 PMC: 10922399. DOI: 10.1161/ATVBAHA.123.320045.


The Effect of Biological Sex on Arterial Stiffness and Renin-Angiotensin-Aldosterone System Activity in Response to Cyclooxygenase-2 (COX-2) Inhibition.

Rytz C, Dumanski S, Sola D, Ahmed S CJC Open. 2023; 5(2):112-119.

PMID: 36880076 PMC: 9984894. DOI: 10.1016/j.cjco.2022.11.011.


Drugs for the prevention and treatment of COVID-19 and its complications: An update on what we learned in the past 2 years.

Remuzzi G, Schiaffino S, Santoro M, FitzGerald G, Melino G, Patrono C Front Pharmacol. 2022; 13:987816.

PMID: 36304162 PMC: 9595217. DOI: 10.3389/fphar.2022.987816.


References
1.
Kennedy C, Zhang Y, Brandon S, Guan Y, COFFEE K, Funk C . Salt-sensitive hypertension and reduced fertility in mice lacking the prostaglandin EP2 receptor. Nat Med. 1999; 5(2):217-20. DOI: 10.1038/5583. View

2.
Brock T, McNish R, Peters-Golden M . Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J Biol Chem. 1999; 274(17):11660-6. DOI: 10.1074/jbc.274.17.11660. View

3.
McAdam B, Morrison B, Kapoor S, Kujubu D, ANTES L, Lasseter K . Effects of specific inhibition of cyclooxygenase-2 on sodium balance, hemodynamics, and vasoactive eicosanoids. J Pharmacol Exp Ther. 1999; 289(2):735-41. View

4.
Castrop H, Kammerl M, Mann B, Jensen B, Kramer B, Kurtz A . Cyclooxygenase 2 and neuronal nitric oxide synthase expression in the renal cortex are not interdependent in states of salt deficiency. Pflugers Arch. 2001; 441(2-3):235-40. DOI: 10.1007/s004240000438. View

5.
Cheng H, Wang J, Zhang M, Wang S, McKanna J, Harris R . Genetic deletion of COX-2 prevents increased renin expression in response to ACE inhibition. Am J Physiol Renal Physiol. 2001; 280(3):F449-56. DOI: 10.1152/ajprenal.2001.280.3.F449. View